HK1258508A1 - 用免疫球蛋白單可變結構域治療ttp的方法及其用途 - Google Patents

用免疫球蛋白單可變結構域治療ttp的方法及其用途

Info

Publication number
HK1258508A1
HK1258508A1 HK19100857.1A HK19100857A HK1258508A1 HK 1258508 A1 HK1258508 A1 HK 1258508A1 HK 19100857 A HK19100857 A HK 19100857A HK 1258508 A1 HK1258508 A1 HK 1258508A1
Authority
HK
Hong Kong
Prior art keywords
methods
variable domains
single variable
immunoglobulin single
treating ttp
Prior art date
Application number
HK19100857.1A
Other languages
English (en)
Inventor
Christian Duby
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HK1258508A1 publication Critical patent/HK1258508A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK19100857.1A 2014-06-16 2019-01-17 用免疫球蛋白單可變結構域治療ttp的方法及其用途 HK1258508A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30

Publications (1)

Publication Number Publication Date
HK1258508A1 true HK1258508A1 (zh) 2019-11-15

Family

ID=51541255

Family Applications (3)

Application Number Title Priority Date Filing Date
HK18115789.3A HK1256731A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域
HK18115787.5A HK1256730A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域
HK19100857.1A HK1258508A1 (zh) 2014-06-16 2019-01-17 用免疫球蛋白單可變結構域治療ttp的方法及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK18115789.3A HK1256731A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域
HK18115787.5A HK1256730A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域

Country Status (16)

Country Link
US (5) US10858445B2 (zh)
EP (6) EP3366305B1 (zh)
JP (3) JP6688746B2 (zh)
KR (2) KR102403388B1 (zh)
CN (1) CN106559985A (zh)
AU (2) AU2015276237B2 (zh)
CA (1) CA2952103A1 (zh)
ES (5) ES2831865T3 (zh)
HK (3) HK1256731A1 (zh)
IL (1) IL249540B (zh)
NL (1) NL2013007B1 (zh)
PL (5) PL3366305T3 (zh)
PT (5) PT3335724T (zh)
RU (1) RU2704444C2 (zh)
SG (2) SG10201811109PA (zh)
WO (1) WO2015193326A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
WO2019154867A1 (en) * 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023108095A1 (en) * 2021-12-10 2023-06-15 Emory University Polypeptides that bind to von willebrand factor (vwf) al domain or an autoinhibitory module, variants, and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2000046383A2 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004037999A2 (en) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU2004204262B2 (en) 2003-01-10 2010-11-04 Ablynx N.V. Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
JP4829897B2 (ja) 2005-01-14 2011-12-07 アブリンクス ナームローゼ フェンノートシャップ 血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
RU2433139C2 (ru) * 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
CN101977654A (zh) 2008-03-21 2011-02-16 埃博灵克斯股份有限公司 冯威勒布兰特因子特异性结合物及其应用方法
CN102271707B (zh) 2008-10-29 2015-04-08 阿布林克斯公司 单域抗原结合性分子的制剂
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
KR20180129991A (ko) * 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
KR101969515B1 (ko) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.

Also Published As

Publication number Publication date
PL3335723T3 (pl) 2022-07-18
ES2924199T3 (es) 2022-10-05
US10858445B2 (en) 2020-12-08
HK1256731A1 (zh) 2019-10-04
PL3366305T3 (pl) 2021-06-14
KR20170015513A (ko) 2017-02-08
US20180155440A1 (en) 2018-06-07
JP6688746B2 (ja) 2020-04-28
PT3154569T (pt) 2021-06-22
US10919980B2 (en) 2021-02-16
PL3332800T3 (pl) 2021-04-19
SG11201610488QA (en) 2017-01-27
HK1256730A1 (zh) 2019-10-04
PL3154569T3 (pl) 2021-11-02
PT3366305T (pt) 2020-12-21
ES2915473T3 (es) 2022-06-22
AU2021202747B2 (en) 2024-02-15
CN106559985A (zh) 2017-04-05
JP7105260B2 (ja) 2022-07-22
US20180155441A1 (en) 2018-06-07
EP3332800A1 (en) 2018-06-13
KR102568585B1 (ko) 2023-08-18
JP2017519762A (ja) 2017-07-20
US20180155443A1 (en) 2018-06-07
JP2020097600A (ja) 2020-06-25
IL249540B (en) 2021-09-30
NL2013007B1 (en) 2016-07-05
AU2021202747A1 (en) 2021-05-27
EP3335723B1 (en) 2022-03-30
PT3335723T (pt) 2022-05-20
RU2704444C2 (ru) 2019-10-28
PT3332800T (pt) 2020-11-19
RU2017100077A3 (zh) 2018-12-25
US20170210822A1 (en) 2017-07-27
EP4059513A1 (en) 2022-09-21
ES2881331T3 (es) 2021-11-29
KR20220053040A (ko) 2022-04-28
RU2017100077A (ru) 2018-07-12
CA2952103A1 (en) 2015-12-23
KR102403388B1 (ko) 2022-06-03
EP3335723A1 (en) 2018-06-20
IL249540A0 (en) 2017-02-28
SG10201811109PA (en) 2019-01-30
ES2831865T3 (es) 2021-06-09
RU2019131713A (ru) 2019-11-11
PT3335724T (pt) 2022-08-02
WO2015193326A1 (en) 2015-12-23
EP3366305A1 (en) 2018-08-29
PL3335724T3 (pl) 2022-09-19
EP3366305B1 (en) 2020-11-18
EP3154569B1 (en) 2021-04-21
JP2022160431A (ja) 2022-10-19
US20180155442A1 (en) 2018-06-07
EP3335724B1 (en) 2022-06-22
EP3154569A1 (en) 2017-04-19
EP3335724A1 (en) 2018-06-20
AU2015276237A1 (en) 2017-01-19
AU2015276237B2 (en) 2021-02-25
ES2843642T3 (es) 2021-07-19
EP3332800B1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1252697A1 (zh) 抗cd33抗體及其使用方法
HK1252675A1 (zh) 抗cd33抗體及其使用方法
IL247898A0 (en) Anti-ox40 antibodies and methods of use
HK1258508A1 (zh) 用免疫球蛋白單可變結構域治療ttp的方法及其用途
HK1258850A1 (zh) 抗tpbg抗體及使用方法
IL265568A (en) Methods for treating TIM-3 elevation